Advancing foundational research from UCLA and Migal – Galilee Research Institute, ImmPact is working on T-cell therapies for liquid and solid cancers.
ImmPact Bio, a US-based developer of cancer treatments based on research at University of California, Los Angeles (UCLA) and Migal – Galilee Research Institute, picked up $111m in a series B round yesterday.
VenBio Partners, Foresite Capital and Decheng Capital led the round, in which pharmaceutical firms Bukwang Pharmaceutical and Novartis – the latter through its Novartis Venture Fund – also took part.
Additional investors included Surveyor Capital, OrbiMed and RM Global Partners (RMGP).
ImmPact Bio is working on chimeric antigen receptor (CAR) T-cell therapies both for haematological malignancies and solid tumours. Its approach aims to overcome several challenges, such as the immunosuppressive tumour microenvironment, and the company particularly hopes to help patients who have exhausted other options.
The technology is based on work by Yvonne Chen and Antoni Ribas at UCLA, who collaborated with Gideon Gross at the Migal – Galilee Research Institute.
In conjunction with the series B…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
